[EN] DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS<br/>[FR] MACROCYCLES DIAMIDES UTILISÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2016205482A1
公开(公告)日:2016-12-22
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Synthesis of Enzymatically Noncleavable Carbocyclic Nucleosides for DNA−<i>N</i>-Glycosylase Studies
作者:Francis Johnson、Gyorgy Dormán、Robert A. Rieger、Ryuji Marumoto、Charles R. Iden、Radha Bonala
DOI:10.1021/tx9701539
日期:1998.3.1
report the synthesis and incorporation into oligomeric DNA via suitable derivatives, the carbanucleosides 8-oxo-7,8-dihydro-2'-deoxycarbainosine, 8-oxo-7,8-dihydro-2'-deoxycarbaguanosine, and 2'-deoxyaristeromycin. Aristeromycin (1) was deoxygenated at the 2'-position as follows. Treatment of 1 with TPDSCl2 gave the 3',5'-protected derivative 3 (76%) which on phenylthiocarbonylation at the 2'-position
Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3
作者:Nigel Vicker、Helen V. Bailey、Joanna M. Day、Mary F. Mahon、Andrew Smith、Helena J. Tutill、Atul Purohit、Barry V. L. Potter
DOI:10.3390/molecules26237166
日期:——
low nanomolar IC50 17β-HSD3 inhibitors were discovered using N-(2-([2-(4-chlorophenoxy)phenylamino]methyl)phenyl)acetamide (1). The most potent compounds have IC50 values of approximately 75 nM. Compound 29, N-[2-(1-Acetylpiperidin-4-ylamino)benzyl]-N-[2-(4-chlorophenoxy)phenyl]acetamide, has an IC50 of 76 nM, while compound 30, N-(2-(1-[2-(4-chlorophenoxy)-phenylamino]ethyl)phenyl)acetamide, has an IC50
17β-羟基类固醇脱氢酶 3 型 (17β-HSD3) 在睾丸和精囊中高水平表达;它也存在于前列腺组织中,并参与性腺和非性腺睾酮的生物合成。该酶是膜结合的,还没有晶体结构。使用先前建立的同源模型和对接研究,通过基于结构的设计,设计并合成了基于选择性芳基苄胺的抑制剂作为前列腺癌治疗的潜在药物。使用N- (2-([2-(4-氯苯氧基)苯基氨基]甲基)苯基)乙酰胺 ( 1 )发现了有效的、选择性的、低纳摩尔 IC 50 17β-HSD3 抑制剂。最有效的化合物具有大约 75 nM 的 IC 50值。化合物29 , N -[2-(1-Acetylpiperidin-4-ylamino)benzyl] -N -[2-(4-chlorophenoxy)phenyl]acetamide, IC 50为 76 nM,而化合物30 , N -(2- (1-[2-(4-氯苯氧基)-苯基氨基]乙基)苯基)乙酰胺,IC
[EN] METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS<br/>[FR] MÉTHODES ET COMPOSITIONS POUR CIBLER DES TREG AU MOYEN D'INHIBITEURS DE CCR8
申请人:NANJING IMMUNOPHAGE BIOTECH CO LTD
公开号:WO2022000443A1
公开(公告)日:2022-01-06
Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.